argenx NV ADR (ARGX)vsGenerate Biomedicines, Inc. Common Stock (GENB)
ARGX
argenx NV ADR
$807.55
+1.62%
HEALTHCARE · Cap: $48.96B
GENB
Generate Biomedicines, Inc. Common Stock
$15.30
-0.78%
HEALTHCARE · Cap: $1.97B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 13183% more annual revenue ($4.24B vs $31.89M). ARGX leads profitability with a 30.5% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 61/100 (C+).
ARGX
Buy61
out of 100
Grade: C+
GENB
Avoid16
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+60.1%
Fair Value
$2094.01
Current Price
$807.55
$1286.46 discount
Intrinsic value data unavailable for GENB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Strong operational efficiency at 27.4%
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 170.7x book value
Earnings declined 31.9%
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : GENB
GENB has a balanced fundamental profile.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : GENB
The primary concerns for GENB are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ARGX profiles as a growth stock while GENB is a value play — different risk/reward profiles.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (61/100 vs 16/100), backed by strong 30.5% margins and 73.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Generate Biomedicines, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Generate Biomedicines, Inc. is an innovative biotechnology company focused on harnessing the power of genetic engineering to develop protein therapeutics for a range of diseases. By leveraging advanced artificial intelligence and machine learning technologies, Generate Biomedicines aims to streamline the drug discovery process, significantly reducing time and costs associated with traditional methods. The company's proprietary platform enables the rapid design and optimization of therapeutic proteins, positioning it at the forefront of the biopharmaceutical industry. With a strong commitment to improving patient outcomes, Generate Biomedicines continues to expand its pipeline and collaborate with leading partners to bring transformative treatments to market.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?